LAG3 and cancer: The other molecules involved in immune-inhibitory pathways, such as lymphocyte activation gene-3 (LAG-3, CD223), T cell immunoglobulin-3 (TIM-3), and B7 homolog 3 (B7-H3, CD276), which are considered potential targets of cancer immunotherapy, can also be targeted by antibodies [11,12,13].